This activity is intended for MD’s, DO’s PA’s, NP’s, and Chiropractors engaged in the DOT/ FMCSA medical examination and certification/ qualification of commercial motor vehicle drivers.

After completing this activity, the participant should be better able to:

At the conclusion of this activity, the participant should be able to:

• Outline DOT-FMCSA requirements for identifying Obstructive Sleep Apnea in commercial drivers
• Use evidence based screening process to identify drivers at risk for OSA
• Review evidence based research and medical expert reports regarding OSA in commercial drivers
• Outline and give examples to the commercial drivers life style changes to reduce risks of OSA.

Dr. Lawrence Earl, MD
Medical Director
National Academy DOT Medical Examiners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and The National Academy of DOT Medical Examiners (NADME). The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This educational activity for 1.5 contact hour(s) is provided by the Postgraduate Institute for Medicine.

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty members report the following:

Dr. Lawrence Earl, MD, has nothing to disclose.

The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose. The NADME planners have nothing to disclose.

There are no fees for participating and receiving CME credit for this activity. During the period January 1, 2017 through January 1, 2020, participants must read the learning objectives and faculty disclosures and successfully complete the online course and pass the final examination.

After successfully completing the course you will be provided a link to CME University to complete an activity evaluation.

Upon registering and completing the activity evaluation, your certificate will be made available immediately.

Internet

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.